Genome&Company KRX:314130KOSDAQ

지놈앤컴퍼니 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days17
DART filings, 7 days0
Articles tracked48since Sep 11

In Q2 2026, Genome&Company reported revenue of ₩6.3bn, up 7.7% year on year, and an operating loss of ₩8.0bn. Genome&Company (지놈앤컴퍼니) appeared in 17 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 17 articles. The most common catalyst was stakes & m&a (5). It was most often mentioned alongside 글로벌테크놀로지.

Filing signals 4 quarters of losses Screener

Genome&Company quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩6.3bn+7.7%−₩8.0bn
margin −127.5%
−₩42.6bn
Q1 2026₩5.8bn-9.0%−₩6.1bn
margin −105.4%
−₩6.8bn
Q4 2025 derived₩5.9bn-18.9%−₩7.0bn
margin −119.8%
₩14.3bn
Q3 2025₩6.6bn+41.9%−₩8.1bn
margin −123.4%
−₩8.0bn
Q2 2025₩5.8bn-50.0%−₩7.4bn
margin −127.6%
−₩6.8bn
Q1 2025₩6.4bn+49.1%−₩6.7bn
margin −105.5%
−₩7.1bn
Q4 2024 derived₩7.2bn+102.1%−₩5.3bn
margin −73.5%
−₩11.8bn
Q3 2024₩4.6bn+3.7%−₩7.8bn
margin −169.8%
−₩7.2bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Genome&Company top stories 2 weeks, by number of outlets

  1. 1
    지놈앤컴퍼니, 화장품 유통사 올블룸 인수…유이크 美 진출 가속
    7 outlets · 8 articlesFirst report Oct 26 08:40 서울경제
  2. 2
    "AI 신약 개발"…지놈앤컴퍼니, '릴리 튠랩' 참여
    4 outlets · 4 articlesFirst report Oct 20 11:06 뉴시스경제
  3. 3
    지놈앤컴퍼니, 뷰티·에스테틱 美 유통사 ‘올블룸’ 지분 64.46% 인수
    3 outlets · 3 articlesFirst report Oct 26 09:53 더바이오
  4. 4
  5. 5
    지놈앤컴퍼니, 릴리 AI 신약개발 플랫폼 참여…후보물질 최적화 속도
    1 outlets · 2 articlesFirst report Oct 20 10:08 이데일리
  6. 6
    지놈앤컴퍼니, 릴리 AI 신약개발 플랫폼 '튠랩' 합류
    1 outlets · 1 articlesFirst report Oct 21 09:00 한국경제TV

Latest Genome&Company news Korean headlines